These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34894047)

  • 1. Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting.
    Le LV; Blach S; Rewari B; Chan P; Fuqiang C; Ishikawa N; Sharma M; Mangadan-Konath N; Razavi H; Low-Beer D; Razavi-Shearer D
    Liver Int; 2022 Aug; 42(9):1930-1934. PubMed ID: 34894047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global reporting of progress towards elimination of hepatitis B and hepatitis C.
    Cui F; Blach S; Manzengo Mingiedi C; Gonzalez MA; Sabry Alaama A; Mozalevskis A; Séguy N; Rewari BB; Chan PL; Le LV; Doherty M; Luhmann N; Easterbrook P; Dirac M; de Martel C; Nayagam S; Hallett TB; Vickerman P; Razavi H; Lesi O; Low-Beer D
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):332-342. PubMed ID: 36764320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    GBD 2019 Hepatitis B Collaborators
    Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):796-829. PubMed ID: 35738290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global mortality of chronic liver diseases attributable to Hepatitis B virus and Hepatitis C virus infections from 1990 to 2019 and projections to 2030.
    Ou TY; Huy LD; Mayne J; Shih CL; Mai Xuan H; Thi Hong Nguyen N; Nguyen Hoai L; Thi My Bui L; Chang YM; Abdi AA; Hsu SC; Lin HJ; Huang CC
    J Infect Public Health; 2024 Jul; 17(7):102443. PubMed ID: 38838606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance for acute viral hepatitis - United States, 2007.
    Daniels D; Grytdal S; Wasley A;
    MMWR Surveill Summ; 2009 May; 58(3):1-27. PubMed ID: 19478727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
    Dunn R; Musabaev E; Razavi H; Sadirova S; Bakieva S; Razavi-Shearer K; Brigida K; Kamili S; Averhoff F; Nasrullah M
    MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(34):1161-1165. PubMed ID: 32853186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
    Qureshi H; Mahmood H; Sabry A; Hermez J
    J Infect Dis; 2023 Sep; 228(Suppl 3):S204-S210. PubMed ID: 37703344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments.
    Wait S; Kell E; Hamid S; Muljono DH; Sollano J; Mohamed R; Shah S; Mamun-Al-Mahtab ; Abbas Z; Johnston J; Tanwandee T; Wallace J
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):248-255. PubMed ID: 28404097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current and future burden of hepatitis B in Switzerland: a modelling study.
    Negro F; Müllhaupt B; Semela D; Blach S; Bruggmann P; De Gottardi A; Dufour JF; Fraga M; Galante A; Razavi H; Vieira Barbosa J; Razavi-Shearer D
    Swiss Med Wkly; 2023 Jun; 153():40086. PubMed ID: 37410921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030.
    Howell J; Pedrana A; Cowie BC; Doyle J; Getahun A; Ward J; Gane E; Cunningham C; Wallace J; Lee A; Malani J; Thompson A; Hellard ME
    J Gastroenterol Hepatol; 2019 Jan; 34(1):40-48. PubMed ID: 30151932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global trends and the impact of chronic hepatitis B and C on disability-adjusted life years.
    Veracruz N; Gish RG; Cheung R; Chitnis AS; Wong RJ
    Liver Int; 2022 Oct; 42(10):2145-2153. PubMed ID: 35753064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing epidemiology of liver disease in Asia: Dual infection of HBV and HCV.
    Liu CJ; Chen PJ
    Liver Int; 2022 Aug; 42(9):1945-1954. PubMed ID: 34402183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the 2008 economic crisis on the burden of hepatitis B and C diseases in Southern European countries.
    Palladino C; Ramis R; Ezeonwumelu IJ; Biondi A; Carreras G; Fischer F; Gallus S; Golinelli D; Gorini G; Hassan S; Kabir Z; Koyanagi A; Lazarus JV; Mentis AA; Meretoja TJ; Mokdad AH; Monasta L; Mulita F; Postma MJ; Tabarés-Seisdedos R; Thiyagarajan A; Taveira N; Briz V;
    BMC Public Health; 2024 Jun; 24(1):1642. PubMed ID: 38902642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How far are we from viral hepatitis elimination service coverage targets?
    Hutin YJ; Bulterys M; Hirnschall GO
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25050. PubMed ID: 29633520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019.
    Veracruz N; Gish RG; Cheung R; Chitnis AS; Wong RJ
    J Viral Hepat; 2022 May; 29(5):352-365. PubMed ID: 35274406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of hepatitis B elimination in high-income countries with ongoing immigration.
    Tian F; Feld JJ; Feng Z; Sander B; Wong WWL
    J Hepatol; 2022 Oct; 77(4):947-956. PubMed ID: 35483535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress towards elimination of viral hepatitis by 2030 in the WHO Eastern Mediterranean Region, 2019.
    Alaama AS; Khattabi H; Mugisa B; Atta H; Hermez J; Hutin YJ
    Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):862-870. PubMed ID: 35817075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capacity to report on mortality attributable to chronic hepatitis B and C infections by Member States: An exercise to monitor progress towards viral hepatitis elimination.
    Duarte G; Williams CJ; Vasconcelos P; Nogueira P
    J Viral Hepat; 2018 Jul; 25(7):878-882. PubMed ID: 29479771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The case for simplifying and using absolute targets for viral hepatitis elimination goals.
    Polaris Observatory Collaborators
    J Viral Hepat; 2021 Jan; 28(1):12-19. PubMed ID: 32979881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*.
    Hatzakis A; Wait S; Bruix J; Buti M; Carballo M; Cavaleri M; Colombo M; Delarocque-Astagneau E; Dusheiko G; Esmat G; Esteban R; Goldberg D; Gore C; Lok AS; Manns M; Marcellin P; Papatheodoridis G; Peterle A; Prati D; Piorkowsky N; Rizzetto M; Roudot-Thoraval F; Soriano V; Thomas HC; Thursz M; Valla D; van Damme P; Veldhuijzen IK; Wedemeyer H; Wiessing L; Zanetti AR; Janssen HL
    J Viral Hepat; 2011 Sep; 18 Suppl 1():1-16. PubMed ID: 21824223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.